Impressive results from E Merck - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Impressive results from E Merck

Apr 25, 2000

A 10% increase in sales has lead to tripling of profits at the net level. This has to do with the fact that last year the company provided Rs 27 m for the VRS payments to workers and closed its Taloja plant. However, even if one were to add this back to the last year's pre-tax profit, the net profit has still grown by 55%.

Besides, E Merck repaid almost a third of its borrowings last year which has led to a 32% decline in the interest payments and contributed to the surge in the bottomline.

(Rs m) FY99 FY00 Change
Sales 615 676 9.8%
Other Income 10 13 23.8%
Expenditure 575 589 2.5%
Operating Profit (EBDIT) 41 87 113.8%
Operating Profit Margin (%) 7% 13%  
Interest 10 7 -32.1%
Depreciation 17 21 20.8%
Profit before Tax 24 72 201.7%
Other Adjustments      
Tax 7 22 234.3%
Profit after Tax/(Loss) 18 51 189.7%
Net profit margin (%) 2.8% 7.5%  

E Merck derives almost 70% of the vitamins with three products Evion, Polybion and Neurobion contributing almost 45% of the company's turnover. All the three are under price control and are likely to remain that way for some time to come.

The company has introduced products in the cardiovascular and dermatological segments both of which are out of price control and these should boost revenues in the future.

The company's stock price performance is in sharp contrast to its fundamentals. In line with other pharmaceutical stocks the company's stock has also been hammered and actually touched its 52 week low (Rs 260) yesterday! This could be partially explained by the apprehension created due to a wrong news report which said that government has banned vitamins B1, B6 and B12 from January 2001. Since E Merck is the bigget player in this segment, this meant that the future revenues would be hit. However, the actual fiat was with respect of injectibles of an irrational combination of B1, B6 and B12 which has already been banned worldwide. Thus the company can continue selling these vitamins in the oral or injectable form except for the particular combination. However the fall in stock price represents a good opportunity for long term investors.

Equitymaster requests your view! Post a comment on "Impressive results from E Merck". Click here!


More Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 28, 2020 (Close)


  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks